The clinical and therapeutical aspects of schizo-affective psychosis.
According to our three series of examinations, we have found a way of differentiating between nuclear schizophrenics and manic-depressives in schizo-affective disorders. Only a very small amount of all people diagnosed as schizophrenics (about 3%) have to be put under the category of schizo-affective disorders (Legierungspsychose) sensu strictiori. But in this well-defined group, there is a relation between the symptomatology of the acute stage and the long-term course of the disorder. There is also a better indication for long-term therapy in schizo-affective disorders, because the differentiation in psychopathology also means a better-differentiated therapy with better long-term results.
D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000175:diagnosis; D003702:Delusions / Q000523:psychology; D003937:Diagnosis, Differential; D004359:Drug Therapy, Combination; D005476:Fluphenazine / Q000627:therapeutic use; D006801:Humans; D011379:Prognosis; D011618:Psychotic Disorders / Q000175:diagnosis* / Q000188:drug therapy / Q000523:psychology; D012559:Schizophrenia / Q000175:diagnosis
D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D005476:Fluphenazine